Morley Device Innovations

Managing Director Donald A. Johnson leads investment decisions. Johnson is also a member of the Morley Research Consortium, which provides clinical and regulatory support to portfolio companies. The overlap suggests a concentrated decision-making structure where the lead investor is also embedded in the technical development pathway.

MDI sources opportunities through its participation in life-science investment conferences, notably the RESI (Redefining Early Stage Investments) series, and through the Morley Research Consortium's clinical networks. Its dual identity as both investor and research operator creates a pipeline that peers relying solely on venture networks may not access, particularly in early-stage medical devices where clinician-entrepreneur relationships are critical.

The Morley Research Consortium functions as a parent or affiliate organization that provides clinical research, trial design, and regulatory strategy support to MDI portfolio companies. Key personnel, including Donald Johnson and Jane Green, hold roles at both entities. This integrated structure means MDI can offer operational clinical support alongside capital, a departure from standard venture-firm practice where such services are outsourced to third-party CROs.

Available information points to a direct-investment model at the early stage. MDI has not publicly disclosed any fund-of-funds commitments or investments through external general partners. Its strategy appears to concentrate on deploying capital directly into companies that can also leverage the Morley Research Consortium for clinical development.

Life2, Inc. was founded by Samuel Marion Wilkes III, a business partner of MDI, and is identified as a key portfolio company and partner. The close relationship between Wilkes, MDI, and the Morley Research Consortium indicates Life2 serves as both a direct investment and a development collaborator, though the specific technology focus of Life2 is not detailed in public records.